Solna, Sweden, 21 July 2022 – Vivesto AB (“Vivesto” or the “Company”), an oncology-focused specialty pharmaceutical company, hereby announces that the Board of Directors of the Company today has appointed Christer Nordstedt as acting CEO of the Company.
Christer assumes the position as acting CEO on 21 July 2022 and will hold the position until the recruitment of a permanent CEO is completed.
Peter Zonabend, Chairman of the Board of Vivesto, says: “We are very pleased to appoint Christer Nordstedt as acting CEO. Christer has a proven track record within R&D and his leadership ensures that we will achieve our goals. With his long and very relevant experience in R&D, Christer will be able to continue the strategic direction of Vivesto to become a strong oncology company through own development and future partnerships.”
Christer Nordstedt is a Doctor of Medicine and has a PhD in Pharmacology and Biochemistry from the Karolinska Institute in Sweden and did his postdoctoral training with the Nobel laureate Paul Greengard at Rockefeller University in New York. Christer has many years of experience, including leading a large number of projects in the pharmaceutical industry from the earliest discovery all the way through clinical development, and has held positions such as Global Head of Specialty Research and Clinical Development and Senior Vice President Global Head of Clinical Development at Teva Pharmaceuticals, Head of R&D at Orion Cooperation as well as Senior Vice President at Hoffman-LaRoche in Basel and at Eli Lilly in Indianapolis. Currently, Christer is Chairman of the Board of WntResearch AB and engaged as a consultant at BioArctic AB. Christer does not own any shares or share-related instruments in Vivesto.
For More Information:
Peter Zonabend, Chairman of the Board of Vivesto
Phone: +46 18-50 54 40
Consilium Strategic Communications (For Vivesto)
Jonathan Birt, Ashley Tapp
Phone: +44 (0) 20 3709 5700
About Vivesto AB
Vivesto is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Vivesto has proprietary drug delivery technology designed to improve solubility, efficacy and safety. Vivesto’s shares are traded on Nasdaq Stockholm (VIVE). To find out more about Vivesto please visit www.vivesto.com.